Structure Therapeutics (NASDAQ:GPCR) Reaches New 52-Week Low – Time to Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $15.31 and last traded at $16.95, with a volume of 1259016 shares changing hands. The stock had previously closed at $15.79.

Analysts Set New Price Targets

Several brokerages recently commented on GPCR. William Blair initiated coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating on the stock. JMP Securities reissued a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Trading Down 7.4 %

The company has a market cap of $867.03 million, a price-to-earnings ratio of -20.43 and a beta of -2.37. The company has a fifty day moving average price of $23.03 and a two-hundred day moving average price of $30.45.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP boosted its holdings in Structure Therapeutics by 2.9% during the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after purchasing an additional 221,851 shares in the last quarter. Janus Henderson Group PLC grew its position in Structure Therapeutics by 5.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock valued at $112,816,000 after acquiring an additional 203,010 shares during the period. Deep Track Capital LP raised its stake in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after acquiring an additional 1,579,492 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after acquiring an additional 575,000 shares during the period. Finally, Capital International Investors boosted its stake in shares of Structure Therapeutics by 6.8% in the 4th quarter. Capital International Investors now owns 1,619,081 shares of the company’s stock valued at $43,909,000 after purchasing an additional 103,059 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.